These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 21327511)

  • 21. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulation: a GP primer on the new oral anticoagulants.
    Brieger D
    Aust Fam Physician; 2014 May; 43(5):254-9. PubMed ID: 24791763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rivaroxaban for the prevention of venous thromboembolism following major orthopedic surgery: the RECORD trials.
    Ageno W
    Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):569-76. PubMed ID: 19505271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dabigatran etexilate: future directions in anticoagulant treatment.
    Schulman S; Reilly PA
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New anticoagulants: moving on from scientific results to clinical implementation.
    Eerenberg ES; van Es J; Sijpkens MK; Büller HR; Kamphuisen PW
    Ann Med; 2011 Dec; 43(8):606-16. PubMed ID: 21864021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct oral anticoagulants: An update.
    Franco Moreno AI; Martín Díaz RM; García Navarro MJ
    Med Clin (Barc); 2018 Sep; 151(5):198-206. PubMed ID: 29295790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Betrixaban (PRT054021): pharmacology, dose selection and clinical studies.
    Chan NC; Hirsh J; Ginsberg JS; Eikelboom JW
    Future Cardiol; 2014 Jan; 10(1):43-52. PubMed ID: 24344662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacologic heterogeneity of new anticoagulants].
    Samamaa MM; Conard J; Flaujac C; Combe S; Horellou MH
    J Mal Vasc; 2011 Dec; 36 Suppl 1():S10-5. PubMed ID: 22177763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management consensus guidance for the use of rivaroxaban--an oral, direct factor Xa inhibitor.
    Turpie AG; Kreutz R; Llau J; Norrving B; Haas S
    Thromb Haemost; 2012 Nov; 108(5):876-86. PubMed ID: 23014816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.
    Akwaa F; Spyropoulos AC
    Hosp Pract (1995); 2013 Feb; 41(1):8-18. PubMed ID: 23466963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.
    Milling TJ; Ziebell CM
    Trends Cardiovasc Med; 2020 Feb; 30(2):86-90. PubMed ID: 30952383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
    Kansal AR; Zheng Y; Pokora T; Sorensen SV
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):225-37. PubMed ID: 23953910
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factor Xa and thrombin as targets for new oral anticoagulants.
    Weitz JI
    Thromb Res; 2011 Jan; 127 Suppl 2():S5-S12. PubMed ID: 21193114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel oral anticoagulants and their role in clinical practice.
    Wittkowsky AK
    Pharmacotherapy; 2011 Dec; 31(12):1175-91. PubMed ID: 22122180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New oral anticoagulants in elderly patients.
    Barco S; Cheung YW; Eikelboom JW; Coppens M
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):215-24. PubMed ID: 23953909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
    Adam SS; McDuffie JR; Lachiewicz PF; Ortel TL; Williams JW
    Ann Intern Med; 2013 Aug; 159(4):275-84. PubMed ID: 24026260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using new oral anticoagulants in patients undergoing major orthopedic surgery.
    Bass AR
    Curr Rheumatol Rep; 2015 Apr; 17(4):25. PubMed ID: 25854486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic and pharmacokinetic basics of rivaroxaban.
    Kreutz R
    Fundam Clin Pharmacol; 2012 Feb; 26(1):27-32. PubMed ID: 21848931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pros and cons of new oral anticoagulants.
    Bauer KA
    Hematology Am Soc Hematol Educ Program; 2013; 2013():464-70. PubMed ID: 24319220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.